The board of directors of the U.S. listed company Enlivex Therapeutics has approved the purchase of one million dollars in Bitcoin as a reserve asset

According to Globenewswire, the US-listed company Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced yesterday that its board of directors has approved the purchase of up to $1 million in Bitcoin as part of its cash management strategy. Enlivex CEO Oren Hershkovitz said: "With the growing demand for Bitcoin and its increasing acceptance as a recognized medium of exchange, we believe that Bitcoin will become a strong and diversified reserve asset for the company. With the recent approval of Bitcoin ETFs and increasing support from institutional investors, we believe that Bitcoin can provide potential functional value storage for the company and hedge against inflation in standard currencies."

Enlivex is described as a clinical-stage macrophage reprogramming immunotherapy company.